First Experience With a Whole-Body Spectral Photon-Counting CT Clinical Prototype

Spectral photon-counting computed tomography (SPCCT) technology holds great promise for becoming the next generation of computed tomography (CT) systems. Its technical characteristics have many advantages over conventional CT imaging. For example, SPCCT provides better spatial resolution, greater dose efficiency for ultra-low-dose and low-dose protocols, and tissue contrast superior to that of conventional CT. In addition, SPCCT takes advantage of several known approaches in the field of spectral CT imaging, such as virtual monochromatic imaging and material decomposition imaging. In addition, SPCCT takes advantage of a new approach in this field, known as K-edge imaging, which allows specific and quantitative imaging of a heavy atom-based contrast agent. Hence, the high potential of SPCCT systems supports their ongoing investigation in clinical research settings. In this review, we propose an overview of our clinical research experience of a whole-body SPCCT clinical prototype, to give an insight into the potential benefits for clinical human imaging on image quality, diagnostic confidence, and new approaches in spectral CT imaging.

Automated summary

Spectral photon-counting computed tomography (SPCCT) technology shows many advantages over conventional CT imaging, such as better spatial resolution, greater dose efficiency, and superior tissue contrast. It also utilizes known approaches like virtual monochromatic imaging and material decomposition imaging, as well as a new approach called K-edge imaging. Due to its high potential, SPCCT systems are being researched in clinical settings.